Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBT (2022 - 2025)

Stoke Therapeutics has reported EBT over the past 4 years, most recently at -$57.8 million for Q4 2025.

  • Quarterly results put EBT at -$57.8 million for Q4 2025, down 441.27% from a year ago — trailing twelve months through Dec 2025 was -$6.8 million (up 92.4% YoY), and the annual figure for FY2025 was -$6.8 million, up 92.3%.
  • EBT for Q4 2025 was -$57.8 million at Stoke Therapeutics, down from -$39.6 million in the prior quarter.
  • Over the last five years, EBT for STOK hit a ceiling of $114.2 million in Q1 2025 and a floor of -$57.8 million in Q4 2025.
  • Median EBT over the past 4 years was -$25.7 million (2022), compared with a mean of -$18.9 million.
  • Peak annual rise in EBT hit 532.84% in 2025, while the deepest fall reached 441.27% in 2025.
  • Stoke Therapeutics' EBT stood at -$25.7 million in 2022, then decreased by 5.07% to -$27.0 million in 2023, then soared by 60.43% to -$10.7 million in 2024, then crashed by 441.27% to -$57.8 million in 2025.
  • The last three reported values for EBT were -$57.8 million (Q4 2025), -$39.6 million (Q3 2025), and -$23.5 million (Q2 2025) per Business Quant data.